Cantargia AB: Cantargia to host R&D Day on nadunolimab combi

STOCKHOLM, June 9, 2022 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing

Related Keywords

Stockholm , Sweden , Belgium , Gasthuisberg , Region Flamande , Madrid , Spain , California , United States , Leuven , Poland , Warsaw , L67 , Belgian , Los Angeles , Sudheer Doss , Prnewswire Cantargia , Luniversidad Complutense , Luis Paz , Eric Van Cutsem , Van Cutsem , University Of California , Belgian Foundation , University Of Warsaw , Oncology Department , University Hospitals Gasthuisberg , National Oncology Research Center , Pancreatic Cancer Action Network Pan , Nasdaq Stockholm , Prof Eric Van Cutsem , Prof Van Cutsem , Chief Business Officer , Pancreatic Cancer Action Network , Division Head , Digestive Oncology , Medical University , Belgian Royal Academy , Luis Paz Ares , Medical Oncology Department , Hospital Universitario , Associate Professor , Lung Cancer Unit , Cantargia , Most , Adunolimab , Ombinational , Synergy , Pancreatic , Dancer , Mall , Fell , Young ,